![[Podcast] Trial Trailblazers: Behind clinical breakthroughs](https://imgproxy.divecdn.com/cr_gUY8HHfHKWVfM5mEkCyXB9OzVqKd0L_Zq5ZJQSoM/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlX1BvZGNhc3RfY292ZXIxMzQ2eDcyOV9SMi5wbmc=.webp)
Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus
One day before the potential FDA approval of a rival respiratory syncytial virus monoclonal antibody from Merck, Sanofi has revealed an aggressive supply effort for its RSV blockbuster Beyfortus, including a plan to begin shipping its AstraZeneca-partnered shot early in the third quarter.
One day before the potential FDA approval of a rival respiratory syncytial virus monoclonal antibody from Merck, Sanofi has revealed an aggressive supply effort for its RSV blockbuster Beyfortus, including a plan to begin shipping its AstraZeneca-partnered shot early in the third quarter.
